Review Article

Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis

Siya Hu,1 Yunnan Jing,2 Fangyuan Liu,1 and Fengjuan Han3

1Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China
2Department of Acupuncture and Moxibustion, Heilongjiang University of Chinese Medicine, Harbin 150040, China
3Department of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, China

Correspondence should be addressed to Fengjuan Han; hanfengjuan2004@163.com

Received 25 March 2022; Accepted 21 July 2022; Published 8 August 2022

1. Introduction

Ovarian cancer is the most lethal of the gynecologic malignancies, with 314,000 new cases and 207,000 deaths worldwide in 2020, and its morbidity and mortality are increasing year by year [1, 2]. Ovarian cancer is not a single disease; it can be divided into at least five different histological subtypes with different biological and molecular properties. Moreover, the onset and progression of ovarian cancer are insidious, usually diagnosed late and difficult to treat [3, 4]. Therefore, it is of great significance to identify genes associated with high risk of ovarian cancer.

DNA damage caused by endogenous (e.g., chemical modifications and replication errors) and exogenous (e.g., ultraviolet radiation, ionizing radiation, and various chemicals) factors can give rise to genomic instability and somatic mutations [5, 6]. The accumulation of abnormal somatic mutations can trigger malignant cell transformation [7], which is a crucial cause of carcinogenesis and malignant tumor progression. Of all the DNA damage, DNA double-
Records identified through database searching (n = 137)
  PubMed (n = 20)
  Embase (n = 33)
  Web of Science (n = 61)
  Cochrane library (n = 0)
  CNKI (n = 22)
  Wanfang (n = 1)

Additional record identified through searching the references of the eligible (n = 1)

Records after removing duplicates (n = 80)

Records excluded (n = 71)
  Not reporting of the genotype (n = 17)
  Not relevant to ovarian cancer (n = 19)
  Review and meta-analysis (n = 21)
  Not clinical studies (n = 4)
  Not case-control studies (n = 3)
  Conference abstract (n = 5)
  Duplicate data (n = 2)

9 Articles (12 studies) included for meta-analysis

Figure 1: Flowchart of literature selection process.

Table 1: Main characteristics of the studies included in the meta-analysis.

| First author | Year | Country | Ethnicity | Cases/controls | Cases | Controls | HWE | Quality score |
|--------------|------|---------|-----------|----------------|-------|----------|-----|--------------|
| Kumar        | 2021 | India   | Caucasian | 200/200        | 136   | 140      | 0.131 | 7            |
| Smolarz      | 2019 | Poland  | Caucasian | 600/600        | 147   | 117      | 0.118 | 8            |
| Mackawy      | 2019 | Egypt   | Caucasian | 50/20          | 21    | 14       | 0.094 | 7            |
| Michalska    | 2016 | Poland  | Caucasian | 700/700        | 180   | 150      | 0.892 | 8            |
| Gao          | 2015 | China   | Asian     | 70/70          | 62    | 60       | 0.520 | 8            |
| Monteiro     | 2014 | Brazil  | Mixed     | 70/70          | 32    | 32       | 0.368 | 8            |
| Beesley      | 2007 | Australia| Caucasian | 731/747       | 291   | 288      | 0.950 | 7            |
| Webb         | 2005 | Australia| Caucasian | 543/1125      | 229   | 438      | 0.420 | 8            |
| Auranen1     | 2005 | UK      | Caucasian | 749/830       | 297   | 318      | 0.248 | 7            |
| Auranen2     | 2005 | US      | Caucasian | 270/344       | 125   | 130      | 0.111 | 7            |
| Auranen3     | 2005 | Denmark | Caucasian | 361/891       | 144   | 358      | 0.080 | 7            |
| Auranen4     | 2005 | UK      | Caucasian | 290/1784      | 130   | 728      | 0.806 | 7            |

Table 2: Results of meta-analysis under different genetic models.

| Genetic models       | \(I^2\) (%) | Model for analysis | \(P_{H}\) | OR (95% CI)      | \(P_Z\) |
|----------------------|-------------|--------------------|-----------|------------------|---------|
| G versus A           | 9.8         | FEM                | 0.349     | 1.07 (1.01, 1.13) | 0.018   |
| GG versus AA         | 5.2         | FEM                | 0.395     | 1.11 (0.99, 1.25) | 0.08    |
| GA versus GG         | 0.0         | FEM                | 0.485     | \textbf{0.88 (0.81, 0.96)} | \textbf{0.003} |
| GG+GA versus AA      | 0.0         | FEM                | 0.672     | 1.04 (0.94, 1.16) | 0.468   |
| GG versus GA+AA      | 13.4        | FEM                | 0.314     | \textbf{0.89 (0.82, 0.96)} | \textbf{0.004} |

Bonferroni correction for multiple testing was applied (\(P\) value threshold 0.01).
Table 3: Meta-analysis results of XRCC3 rs861539 polymorphism in different subgroups.

| Genetic models | Subgroup | I² (%) | Model for analysis | P_{H} | OR (95% CI) | P_{Z} |
|----------------|----------|--------|--------------------|-------|-------------|-------|
| G versus A     | Ethnicity|        |                    |       |             |       |
| Caucasian      |          | 25.7   | FEM                | 0.207 | 1.07 (1.01, 1.13) | 0.017 |
| Asian          |          | NA     | FEM                | NA    | 1.00 (0.40, 2.48) | 1.0   |
| Mixed          |          | NA     | FEM                | NA    | 1.00 (0.60, 1.66) | 1.0   |
| Control source |          |        |                    |       |             |       |
| Population     |          | 0.0    | FEM                | 0.865 | 1.04 (0.98, 1.12) | 0.194 |
| Hospital       |          | 57.3   | REM                | 0.071 | 1.08 (0.86, 1.35) | 0.496 |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.675 | 1.04 (0.97, 1.12) | 0.264 |
| Sequencing     |          | 0.0    | FEM                | 0.909 | 1.05 (0.91, 1.22) | 0.491 |
| PCR-RFLP       |          | 58.4   | REM                | 0.065 | 1.08 (0.87, 1.33) | 0.50  |
| GG versus AA   | Ethnicity|        |                    |       |             |       |
| Caucasian      |          | 13.4   | FEM                | 0.319 | 1.12 (0.99, 1.26) | 0.069 |
| Asian          |          | NA     | FEM                | NA    | 0.21 (0.01, 4.39) | 0.31  |
| Mixed          |          | NA     | FEM                | NA    | 1.00 (0.26, 3.79) | 1.0   |
| Control source |          |        |                    |       |             |       |
| Population     |          | 0.0    | FEM                | 0.910 | 1.04 (0.90, 1.20) | 0.603 |
| Hospital       |          | 46.4   | FEM                | 0.133 | **1.30 (1.05, 1.62)** | **0.016** |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.745 | 1.04 (0.89, 1.22) | 0.611 |
| Sequencing     |          | 4.4    | FEM                | 0.306 | 1.00 (0.73, 1.37) | 0.996 |
| PCR-RFLP       |          | 30.9   | FEM                | 0.227 | **1.31 (1.06, 1.62)** | **0.013** |
| GG versus AA   | Control source| |                    |       |             |       |
| Population     |          | 0.0    | FEM                | 0.613 | 0.90 (0.82, 0.99) | 0.029 |
| Hospital       |          | 27.7   | FEM                | 0.246 | 0.81 (0.67, 0.98) | 0.028 |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.420 | 0.91 (0.81, 1.01) | 0.084 |
| Sequencing     |          | 0.0    | FEM                | 0.50  | 0.83 (0.67, 1.03) | 0.097 |
| PCR-RFLP       |          | 26.7   | FEM                | 0.252 | 0.83 (0.69, 1.00) | 0.048 |
| GA versus GG   | Control source| |                    |       |             |       |
| Population     |          | 0.0    | FEM                | 0.607 | 1.04 (0.94, 1.16) | 0.434 |
| Hospital       |          | 27.7   | FEM                | 0.599 | 0.58 (0.20, 1.70) | 0.321 |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.607 | 1.04 (0.94, 1.16) | 0.434 |
| Sequencing     |          | 0.0    | FEM                | 0.50  | 0.83 (0.67, 1.03) | 0.097 |
| PCR-RFLP       |          | 26.7   | FEM                | 0.252 | 0.83 (0.69, 1.00) | 0.048 |
| GG+GA versus AA| Control source| |                    |       |             |       |
| Population     |          | 0.0    | FEM                | 0.879 | 0.98 (0.86, 1.12) | 0.815 |
| Hospital       |          | 13.8   | FEM                | 0.323 | 1.14 (0.96, 1.35) | 0.135 |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.709 | 1.00 (0.86, 1.16) | 0.958 |
| Sequencing     |          | 1.3    | FEM                | 0.314 | 0.92 (0.68, 1.23) | 0.568 |
| PCR-RFLP       |          | 0.0    | FEM                | 0.528 | 1.15 (0.97, 1.36) | 0.116 |
| GG versus GA+AA| Caucasian|        |                    |       |             |       |
| Population     |          | 28.0   | FEM                | 0.187 | 0.89 (0.82, 0.96) | 0.004 |
| Detection method|          |        |                    |       |             |       |
| TaqMan         |          | 0.0    | FEM                | 0.709 | 1.00 (0.86, 1.16) | 0.958 |
| Sequencing     |          | 1.3    | FEM                | 0.314 | 0.92 (0.68, 1.23) | 0.568 |
| PCR-RFLP       |          | 0.0    | FEM                | 0.528 | 1.15 (0.97, 1.36) | 0.116 |
| GG versus GA+AA| Asian    |        |                    |       |             |       |
| Population     |          | NA     | FEM                | NA    | 0.77 (0.29, 2.09) | 0.614 |
| Hospital       |          | NA     | FEM                | NA    | 1.00 (0.51, 1.94) | 1.0   |

**Note:** The table shows the meta-analysis results of XRCC3 rs861539 polymorphism in different subgroups. The models include G versus A, GG versus AA, GG versus GA, and GG+GA versus AA, with subcategories for ethnicity, control source, and detection method. The table presents the I² (%) values, the model for analysis (FEM or REM), the P_{H} values, the odds ratios (OR) with 95% CI, and the P_{Z} values.
strand breaks (DSBs) are the most detrimental because there is no intact template strand to ensure accurate repair [7]. DNA double-strand break repair (DSBR) includes homologous recombination (HR) and nonhomologous terminal junction (NHEJ), in which HR is more accurate [7]. X-ray repair cross-complementing 3 (XRCC3) encodes a member of the RecA/RAD51-related protein family and is involved in homologous recombination repair (HRR) of DNA DSBs [8] and cross-link repair [9, 10]. A common polymorphism of the XRCC3 gene, SNP rs861539, is a C-to-T amino acid [8] and cross-link repair [9, 10]. A common polymorphism of the XRCC3 gene, SNP rs861539, is a C-to-T amino acid substitution at codon 241 in exon 7 of XRCC3, which may affect the function of the enzyme and/or its interaction with other proteins involved in DNA damage and repair [11]. XRCC3 polymorphism has been linked to the risk of multiple cancers, such as breast cancer [12, 13], thyroid cancer [13, 14], melanoma skin cancer [15], and lung cancer [16, 17].

Although many studies have explored the association between XRCC3 rs861539 polymorphism and ovarian cancer risk [18–26], the conclusions have been inconsistent. There have also been meta-analyses of the association between XRCC2 polymorphism and ovarian cancer risk [27, 28], but the results need to be supplemented. To obtain more accurate results, more comprehensive studies were included, and meta-analysis was performed to assess the association of XRCC3 rs861539 polymorphisms with ovarian cancer risk.

### 2. Materials and Methods

**2.1. Search Strategy.** To identify eligible case-control studies, we conducted a comprehensive search across six databases (PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and China Wanfang Database) for studies published up to December 2021. We searched the databases using combinations of the following keywords: “XRCC3 or X-ray repair cross-complementing 3 or Thr241Met or rs861539 or 18067C/T” and “ovarian cancer” and “polymorphism or polymorphisms.” Additional articles were searched by checking the references of relevant studies.

**2.2. Selection Criteria.** The studies included in this meta-analysis need to meet the following criteria: (1) focusing on the association of XRCC3 polymorphism rs861539 with ovarian cancer risk, (2) case-control studies, and (3) providing sufficient information on genotype frequency in the case and control groups. The main reasons for exclusion were as follows: (1) reviews, cell or animal studies, and meta-analyses; (2) information on genotype frequency is unclear or absent; and (3) studies contained duplicate data.

#### 2.3. Data Extraction.** Two reviewers independently screened the literature according to the selection criteria, extracted essential data from the included studies, and then cross-checked to reach a consensus. The essential data we extracted included the first author’s name, year of publication, country, ethnicity, total number of cases and controls, genotype frequency of the case group and the control group, and value of Hardy-Weinberg equilibrium (HWE). If an article had a case-control series of studies, we treated each study as an individual study in this meta-analysis.

#### 2.4. Quality Assessment.** The quality of the included studies was assessed using the Newcastle-Ottawa scale [29], which is divided into three dimensions, including selection, comparability and exposure. Studies with a maximum score of 9 on the scale and a score of less than 5 will be excluded.

#### 2.5. Statistical Analysis.** We assessed the association between XRCC3 rs861539 polymorphism and ovarian cancer risk using odds ratios (ORs) and 95% confidence intervals (CIs) in five genetic models, including homozygote model (GG vs. AA), heterozygote model (GA vs. GG), dominant model (GA+AA vs. GG), recessive model (GG+GA vs. AA), and additive model (G vs. A) [13, 30]. Bonferroni correction was applied to avoid multiple testing error, and \( P < 0.01 \) (0.05/5) was considered statistically significant. Chi-square-based Q statistic test and \( I^2 \) value were used to test heterogeneity between studies. When \( P < 0.1 \) or \( I^2 > 50\% \), significant inter-study heterogeneity was indicated, and random effect model was used for analysis; otherwise, fixed effect model was used instead [31]. Subgroup analyses based on ethnicity, control source, and detection method were performed to explore specific associations [32]. Sensitivity analysis was carried out by removing one article at a time. We evaluated publication bias using funnel plots, Begg’s test, and Egger’s test. The funnel plot is to observe whether the two sides are symmetrical, and the other two depend on the size of \( P \) value. \( P < 0.05 \) indicates that the meta-analysis may have publication bias. The analysis for

### Table 3: Continued.

| Genetic models | Subgroup | \( I^2 \) (%) | Model for analysis | \( P_{10} \) | OR (95% CI) | \( P_Z \) |
|---------------|----------|--------------|-------------------|-----------|-----------|---------|
| Control source | Population | 0.0 | FEM | 0.702 | 0.91 (0.83, 1.00) | 0.05 |
| | Hospital | 52.6 | REM | 0.097 | 0.86 (0.62, 1.19) | 0.358 |
| Detection method | TaqMan | 0.0 | FEM | 0.494 | 0.92 (0.83, 1.02) | 0.114 |
| | Sequencing | 0.0 | FEM | 0.815 | 0.87 (0.71, 1.07) | 0.179 |
| | PCR-RFLP | 55.4 | REM | 0.081 | 0.89 (0.64, 1.22) | 0.462 |

Bonferroni correction for multiple testing was applied (ethnicity and detection method group: \( P \) value threshold 0.016; control source group: \( P \) value threshold 0.025).
Figure 2: Continued.
the present study was completed by Stata software 16.0 (StataCorp, College Station, TX, USA).

2.6. Trial Sequential Analysis. Meta-analysis may lead to false-positive and false-negative results due to random error and lack of statistical accuracy [33]. We conducted TSA to estimate the required information size (RIS) and the reliability of the results based on 5% risk of type I error ($\alpha = 0.05$, two sided), 80% power of study ($\beta = 0.20$), and a case-control event proportion calculated from meta-analysis [34]. TSA was performed using TSA 0.9.5.10 Beta software (Copenhagen Trial Unit, Denmark).

3. Results

3.1. Literature Search and Study Characteristics. According to the search strategy, we found 137 articles in the database (20 in PubMed, 33 in Embase, 61 in Web of Science, 22 in China National Knowledge Infrastructure, and 1 in China Wanfang Database). And 1 article was identified through searching the references of the eligible. Of these, 129 articles were further excluded due to duplicates (58), no reporting of the genotype (17), unrelated to ovarian cancer (19), reviews and meta-analyses (21), nonclinical studies (4), non-case-control studies (3), conference abstracts (5), and duplicate data (2). Ultimately, 9 articles with 12 studies were included for meta-analysis [18–26]. The flowchart of the literature selection process is shown in Figure 1.

The 12 studies included 4,634 cases of ovarian cancer and 7,381 controls, with 10 studies conducted in Caucasians [18–21, 24–26], one in Asians [22], and one in a mixed population [23]. The main information for each study is presented in Table 1. The distribution of all control genotypes included in the study conformed to HWE ($P > 0.05$).

![Funnel plot with pseudo 95% confidence limits](image-url)

Figure 2: Funnel plots of XRCC3 rs861539 and ovarian cancer risk: (a) G vs. A; (b) GG vs. AA; (c) GA vs. GG; (d) GG+GA vs. AA; (e) GG vs. GA+AA.
Meta-analysis estimates, given named study is omitted

| Study             | Estimate | Lower CI limit | Upper CI limit |
|-------------------|----------|----------------|----------------|
| Auranen 1 (2005)  | 0.99     | 1.01           | 1.07           |
| Auranen 2 (2005)  | 1.13     | 1.14           |                |
| Auranen 3 (2005)  |          |                |                |
| Auranen 4 (2005)  |          |                |                |
| Beesley (2007)    |          |                |                |
| Gao (2015)        |          |                |                |
| Kumar (2021)      |          |                |                |
| Mackawy (2019)    |          |                |                |
| Michalska (2016)  |          |                |                |
| Monteiro (2014)   |          |                |                |
| Smolarz (2019)    |          |                |                |
| Webb (2005)       |          |                |                |

Figure 3: Continued.
Figure 3: Continued.
3.2. Meta-Analysis and Subgroup Analyses. The meta-analysis results of XRCC3 rs861539 polymorphism and ovarian cancer risk are shown in Table 2. After Bonferroni correction, we found a close association between XRCC3 rs861539 polymorphism and ovarian cancer risk in two genetic models (GA vs. GG: OR = 0.89, 95%CI = 0.82-0.96, \( P = 0.004 \); GG vs. GA+AA: OR = 0.89, 95%CI = 0.82-0.96, \( P = 0.004 \)), while no significant association was found in the other three genetic models (G vs. A: OR = 1.07, 95%CI = 1.01-1.13, \( P = 0.018 \); GG vs. AA: OR = 1.11, 95%CI = 0.99-1.25, \( P = 0.08 \); GG+GA vs. AA: OR = 1.04, 95%CI = 0.94-1.16, \( P = 0.468 \)).

We implemented subgroup analyses of five genetic models based on ethnicity, control source, and detection method (Table 3). In the ethnicity-based subgroup analysis, XRCC3 rs861539 was associated with a reduced risk of ovarian cancer in Caucasian populations based on the heterozygote model (GA vs. GG: OR = 0.88, 95%CI = 0.81-0.96, \( P = 0.004 \)) and dominant model (GG vs. GA+AA: OR = 0.88, 95%CI = 0.81-0.96, \( P = 0.004 \)). In the subgroup analysis based on control source, hospital-based was significantly increased in the homozygote model (GG vs. AA: OR = 1.30, 95%CI = 1.05-1.62, \( P = 0.016 \)). In subgroup analyses based on detection method, PCR-RFLP was associated with a significant increase in ovarian cancer risk in the homozygote model (GG vs. AA: OR = 1.31, 95%CI = 1.06-1.62, \( P = 0.013 \)).

3.3. Publication Bias and Sensitivity Analysis. Funnel plots of XRCC3 rs861539 and ovarian cancer risk are shown in Figure 2. Begg’s and Egger’s test results are as follows: additive model \( P = 0.732 \) and 0.087, homozygote model \( P = 0.193 \) and 0.028, heterozygote model \( P = 0.732 \) and 0.626, recessive model \( P = 0.064 \) and 0.012, dominant model: \( P = 0.945 \) and 0.325. Egger’s test \( P < 0.05 \) in both homozygote and recessive models, indicating publication bias existed in the two models. Sensitivity analysis results illustrated that our results are reliable (Figure 3).

3.4. Trial Sequential Analysis. In this meta-analysis, two genetic models produced statistically significant in the estimation of correlation between XRCC3 rs861539 polymorphism and ovarian cancer risk. Therefore, we conducted TSA to analyze the heterozygote model (GA vs. GG) and the dominant model (GG vs. GA+AA). As shown in Figures 4(a) and 4(b), the Z-curve crossed the traditional boundary value, but did not cross the TSA boundary value, and the accumulated information did not meet the required information size (RIS), indicating that the meta-analysis may have obtained false-positive conclusions. Therefore, more case-control trials should be included in the future to confirm the conclusions.

4. Discussion

In the past few years, the Cancer Genome Project and the Cancer Genome Atlas have intersected with the field of DNA repair, revealing specific characteristics of DNA damage and DNA repair errors in various cancers [5], which has brought more attention to DNA repair genes in recent years. Germline or somatic mutations in HR genes have been found in about one-third of ovarian cancers [4], and
approximately 50% of high-grade serous ovarian cancers (HGSOCs) are defective in HR DNA repair pathways [35–37]. Mutations in genes involved in DNA repair, such as BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, BARD1, CHEK2, MRE11A, RAD50, ATM, and TP53, have been found to increase the risk of ovarian cancer [38–40]. As a central role in HR, XRCC3 interacts and stabilizes with Rad51 [9] and plays an important role in preventing genomic instability and the generation of tumorigenic mutations [8]. Shi et al. [41] reported that high XRCC3 expression related to poor OS (Overall Survival) data, suggesting that high XRCC3 mRNA levels might play oncogenic roles in breast cancer. Roos et al. [42] reported that glioma overexpressed XRCC3 compared with normal brain tissue. By downregulating the expression of XRCC3 by interference RNA, it was proved that XRCC3 can protect glioma cells from germ-cell death, apoptosis, and cell cycle inhibition induced by temozolomide. However, Cheng et al. [43] presented that reduced XRCC3 expression leads to increased DNA adducts that contribute to lung tumorigenesis in non-smokers. Todorovic et al. [44] suggested that the ability of tumor cells to induce an effective DNA damage response immediately after exposure to DNA damage agents promotes drug resistance. Failure to activate DNA repair adequately, on the other hand, can lead to tumor cell death.

A number of studies have reported an association between XRCC3 rs861539 polymorphism and ovarian cancer risk [18–26]. Michalska et al. [21] reported that XRCC3

![Figure 4: Trial sequential analysis for the meta-analysis of XRCC3 rs861539 and ovarian cancer risk under (a) GA vs. GG and (b) GG vs. GA+AA.](image)
Thr241Met polymorphism may be positively associated with the incidence of ovarian cancer in Polish women. Smolarz et al. [19] found that homozygotes for the Thr241Met polymorphism reduced ovarian cancer risk. However, the study by Kumar et al. [18] showed that the XRCC3 rs861539 polymorphism was not associated with ovarian cancers in the South Indian population. Therefore, the conclusions of the current research on the relationship between the two are inconsistent. Two previous meta-analyses have explored their relationship. A meta-analysis in 2013 reported the association between Thr241Met polymorphism and ovarian cancer risk and found no significant association [28]. In 2021, a meta-analysis reported no association between the Thr241Met polymorphism and risk of gynecologic malignancies, but found a significantly increased risk of gynecologic malignancies in Asians in an ethnicity-based subgroup analysis. Subgroup analyses were then performed based on tumor type and found no increased risk of ovarian cancer in Asians [27]. This is consistent with our findings on Asians. However, the two meta-analyses did not include all studies related to XRCC3 rs861539 polymorphism and ovarian cancer risk. Therefore, 4,634 ovarian cancer cases and 7,381 controls from 12 studies in 9 articles were included in our meta-analysis.

For the overall data, the current meta-analysis showed an association between XRCC3 rs861539 polymorphism and ovarian cancer risk in the heterozygote model and the dominant model. In the subgroup analysis based on ethnicity, we found that XRCC3 rs861539 was associated with ovarian cancer risk in Caucasians. In addition, after stratifying patients separately according to the control source and detection method, hospital-based studies and PCR-RFLP-based studies were found to be more associated with ovarian cancer risk. In these subgroup analyses, we suspect that ethnicity, control source, and detection method may be the sources of interstudy heterogeneity.

Compared with previous meta-analyses, this meta-analysis included the most comprehensive research with enough samples for in-depth analysis, but it still had some limitations. Firstly, some studies lacked information on subjects’ age, age at menopause, and family history, making it impossible to subgroup these factors, which reduces the comprehensiveness of the results. Secondly, many of the relevant studies have been conducted among Caucasians, with fewer studies involving Asians. Thirdly, the interactions of gene–gene and gene–environment may have influenced our results [31, 45]. Fourthly, we searched only Chinese and English databases and may have overlooked some studies published in other languages. Fifthly, the heterogeneities of ethnicity, control source, and detection method all might induce the bias. Finally, as indicated by the TSA results, the inclusion of limited cases and controls reduces the representativeness of the conclusions. Therefore, the conclusion of this meta-analysis needs to be confirmed by more case-control trials.

5. Conclusion
In conclusion, the present meta-analysis suggests that the XRCC3 rs861539 polymorphism may be associated with ovarian cancer risk, especially in Caucasians. Considering the limitations of this meta-analysis, large-scale multicenter case-control studies in more different regions will be needed in the future.

Data Availability
The data analyzed in this study are from previously reported studies, which have been cited.

Conflicts of Interest
All authors declared that there is no competing interest.

Authors’ Contributions
Siyang Hu and Yunnan Jing should be considered co-first authors.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (82074484).

References

[1] L. Kuroki and S. R. Guntupalli, “Treatment of epithelial ovarian cancer,” BMJ (Clinical research ed.), vol. 371, article m3773, 2020.
[2] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[3] L. Stephanie, B. Marsela, and A. M. Oza, “Epithelial ovarian cancer: evolution of management in the era of precision medicine,” CA: a Cancer Journal for Clinicians, vol. 69, no. 4, pp. 280–304, 2019.
[4] U. A. Matulonis, A. K. Sood, F. Lesley, B. E. Howitt, S. Jalid, and B. Y. Karlan, “Ovarian cancer,” Nature Reviews. Disease Primers, vol. 2, no. 1, p. 16061, 2016.
[5] A. Tubbs and A. Nussenzweig, “Endogenous DNA damage as a source of genomic instability in cancer,” Cell, vol. 168, no. 4, pp. 644–656, 2017.
[6] C. Gourley, J. Balmaña, J. A. Ledermann et al., “Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 37, no. 25, pp. 2257–2269, 2019.
[7] W. Choi and E. S. Lee, “Therapeutic targeting of DNA damage response in cancer,” International Journal of Molecular Sciences, vol. 23, no. 3, p. 1701, 2022.
[8] K. K. Khanna and S. P. Jackson, “DNA double-strand breaks: signaling, repair and the cancer connection,” Nature Genetics, vol. 27, no. 3, pp. 247–254, 2001.
[9] Z. Bao, Y. Jieliang, L. Bin, M. Qiang, S. Guojun, and H. Ruizhang, “DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis,” International Journal of Clinical and Experimental Medicine, vol. 6, no. 6, pp. 438–443, 2013.
[10] Z. Ping, W. Qin, Q. Qian, and Y. Li-Ke, “XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis,”
Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, p. 1, 2013.
[11] G. Matullo, D. Palli, M. Peluso et al., "XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects," Carcinogenesis, vol. 22, no. 9, pp. 1437–1445, 2001.
[12] R. Taruna, S. Arun, R. K. Kumar, T. Srikanth, V. Sivaramakrishnan, and D. N. Rao, "Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women," PLoS One, vol. 17, no. 1, article e0259761, 2022.
[13] L. Weiqing, M. Shumin, L. Lei, K. Zhiyong, Z. Hongbin, and Y. Jun, "The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case-control studies," BMC Medical Genomics, vol. 14, no. 1, p. 117, 2021.
[14] S. Romana, M. Ishrat, B. Kashif, S. Soma, and K. M. Akhtar, "Haplotype based analysis of XRCC3 gene polymorphisms in thyroid cancer," Cellular Physiology and Biochemistry, vol. 42, no. 1, pp. 22–33, 2017.
[15] F. Jinghua, F. Yuhua, K. Xiaoxiao, and Z. Limin, "XRCC3 T241M polymorphism and melanoma skin cancer risk: a meta-analysis," Oncology Letters, vol. 9, no. 5, pp. 2425–2429, 2015.
[16] C. Hung-Jen, C. Wen-Shin, H. Te-Chun et al., "Contribution of genotyping of DNA double-strand break repair gene XRCC3, gender, and smoking behavior to lung cancer risk in Taiwan," Anticancer Research, vol. 35, no. 7, pp. 3893–3899, 2015.
[17] H. Guohua, C. Shaoxi, W. Wei, Z. Qing, and L. Aihua, "Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies," PLoS One, vol. 8, no. 8, article e68457, 2013.
[18] K. G. Growtham, P. S. F. Durairaj, M. Jovita et al., "Association between RAD51, XRCC2 and XRCC3 gene polymorphisms and risk of ovarian cancer: a case control and an in silico study," Molecular Biology Reports, vol. 48, no. 5, pp. 4209–4220, 2021.
[19] S. Beata, M. M. Michalska, S. Dariusz, R. Hanna, and W. Luiza, "Polymorphism of DNA repair genes via homologous recombination (HR) in ovarian cancer," Pathology Oncology Research, vol. 25, no. 4, pp. 1607–1614, 2019.
[20] A. M. H. Mackawy, S. Shalaby, and O. Y. Megahed, "DNA repair gene (XRCC3) polymorphisms and its association with ovarian carcinoma in Egyptian patients," Gene, vol. 21, article 100584, 2019.
[21] M. M. Michalska, D. Samulak, H. Romanowicz, F. Jabłoński, and B. Smolarz, "Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and ovarian cancer in Polish women," Experimental and Molecular Pathology, vol. 100, no. 2, pp. 243–247, 2016.
[22] M. A. Kayani, S. Khan, R. M. Baig, and I. Mahjabeen, "Association of RAD51 gene G135C and XRCC3 gene T241M polymorphism with ovarian cancer," Modern practical medicine, vol. 27, no. 11, pp. 1405–1407 +1537, 2015.
[23] M. S. Monteiro, D. B. Vilas Boas, C. B. Gigliotti, and D. M. Salvadori, "Association among XRCC1, XRCC3, and BLHXX gene polymorphisms and chromosome instability in lymphocytes from patients with endometriosis and ovarian cancer," Genetics and molecular research: GMR, vol. 13, no. 1, pp. 636–648, 2014.
[24] J. Beesley, S. J. Jordan, A. B. Spurde et al., "Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set," Cancer Epidemiology, Biomarkers & Prevention, vol. 16, no. 12, pp. 2557–2565, 2007.
[25] P. M. Webb, J. L. Hopper, N. Beth et al., "Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer," Cancer Epidemiology, Biomarkers & Prevention, vol. 14, no. 2, pp. 319–323, 2005.
[26] A. Annika, S. Honglin, W. Christy et al., "Polymorphisms in DNA repair genes and epithelial ovarian cancer risk," International Journal of Cancer, vol. 117, no. 4, pp. 611–618, 2005.
[27] Y. Xiangyuan, W. Qianqian, H. Gaofeng, and Y. Hongping, "Association between XRCC3 Thr241Met polymorphism and risk of gynecological malignancies: a meta-analysis," Cancer Genetics, vol. 254-255, pp. 11–17, 2021.
[28] Y. Yulan, L. Hongjie, L. Ruolin et al., "XRCC3 Thr241Met polymorphism and ovarian cancer risk: a meta-analysis," Tumour Biology, vol. 35, no. 3, pp. 2711–2715, 2014.
[29] G. A. Wells, B. Shea, D. O’Connell, and A. Rabello, The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses, Ottawa Hospital Research Institute, Ottawa, 2011.
[30] L. JieNa, P. Lei, Q. Xia, C. HongYan, M. HuiYing, and W. GuoXing, "Association between ERCC2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects," Archives of Gynecology and Obstetrics, vol. 296, no. 3, pp. 551–558, 2017.
[31] W. Bei and Y. Fenlai, "The association between interleukin-1 β gene polymorphisms and the risk of breast cancer: a systematic review and meta-analysis," Archives of Medical Science, vol. 18, no. 1, pp. 1–10, 2022.
[32] Y. Jin, "Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis," Artificial cells, nanomedicine, and biotechnology, vol. 47, no. 1, pp. 2338–2342, 2019.
[33] J. J. Wang, H. Liu, Y. Wang et al., "The polymorphisms of interleukin-12B gene and susceptibility to inflammatory bowel diseases: a meta-analysis and trial sequential analysis," Immunological Investigations, vol. 50, no. 8, pp. 987–1006, 2021.
[34] A. Amar, A. Afzal, S. A. Hussain et al., "Association of vitamin D receptor gene polymorphisms and risk of urolithiasis: results of a genetic epidemiology study and comprehensive meta-analysis," Urolithiasis, vol. 48, no. 5, pp. 385–401, 2020.
[35] P. A. Konstantinopoulos, S. A. Cannistra, F. Helen et al., "Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer," PLoS One, vol. 6, no. 3, article e18202, 2011.
[36] M. Asima, E. Ahmed, C. Aiste et al., "Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors," Clinical Cancer Research, vol. 16, no. 8, pp. 2344–2351, 2010.
[37] A. Mukhopadhyay, E. R. Plummer, A. Elattar et al., "Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival," Cancer Research, vol. 72, no. 22, pp. 5675–5682, 2012.
[38] K. P. Pennington and E. M. Swisher, "Hereditary ovarian cancer: beyond the usual suspects," Gynecologic Oncology, vol. 124, no. 2, pp. 347–353, 2012.
[39] W. Tom, C. Silvia, M. K. Lee et al., “Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 44, pp. 18032–18037, 2011.

[40] B. M. Norquist, M. I. Harrell, M. F. Brady et al., "Inherited mutations in women with ovarian carcinoma," JAMA Oncology, vol. 2, no. 4, pp. 482–490, 2016.

[41] Y. Shi, M. Shen, M. Xu, M. Tao, K. Chen, and Q. Zhu, “Comprehensive analysis of the expression and prognosis for RAD51 family in human breast cancer,” International journal of general medicine, vol. 15, pp. 4925–4936, 2022.

[42] W. P. Roos, L. Frohnapfel, S. Quiros, F. Ringel, and B. Kaina, “XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair,” Cancer Letters, vol. 424, pp. 119–126, 2018.

[43] Y. W. Cheng, F. C. Lin, C. Y. Chen, and N. Y. Hsu, “Environmental exposure and HPV infection may act synergistically to induce lung tumorigenesis in nonsmokers,” Oncotarget, vol. 7, no. 15, pp. 19850–19862, 2016.

[44] V. Todorovic, B. Groselj, M. Cemazar et al., “Expression of DNA-damage response and repair genes after exposure to DNA-damaging agents in isogenic head and neck cells with altered radiosensitivity,” Radiology and Oncology, vol. 56, no. 2, pp. 173–184, 2022.

[45] H. Guisheng, S. Tao, Z. Yazhen et al., “TERT rs10069690 polymorphism and cancers risk: a meta-analysis,” Molecular Genetics & Genomic Medicine, vol. 7, no. 10, article e00903, 2019.